GUILD Learning and Development has launched a new course to educate pharmacists on Aimovig (erenumab), which was recently registered in Australia for migraine prophylaxis (PD 23 Aug).
The course, developed with the support of Novartis, examines the symptoms, pathophysiology and role of pharmacists in the treatment of migraine and introduces the monoclonal antibody - details at myCPD.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 18
